Tau is a protein that builds up and moves between nerve cells in the brains of people living with Alzheimer’s disease, causing damage. Professor Mudher is using clever genetic manipulation in fruit ...

Eli Lilly is still celebrating the FDA approval of its amyloid-directed Alzheimer's therapy Kisunla but has had less fortune with a candidate against tau, another well-established drug target for ...

Researchers found that TBI increases hyperphosphorylated tau, astro- and microgliosis, synaptic dysfunction and cognitive impairments linked to developing Alzheimer’s disease. Furthermore, they found ...

UCB’s bepranemab slowed the accumulation of tau in the brain but did not slow disease progression in its first phase II test in Alzheimer disease (AD), UCB reported. The mixed results are a blow ...

The week after seeing its partner Roche cut and run, UCB has reported the failure of its anti-tau antibody bepranemab to improve cognition and function in people with early Alzheimer’s disease.

Researchers have revealed the role of enzyme TYK2 in the aggregation of tau proteins, which contributes to Alzheimer’s ...

Trimming Alzheimer's-linked proteins This new technique for targeting tau tangles utilizes a 2010 discovery from Dr. Leo ...

A large number of studies over the past 20 years have quantified phosphorylated tau protein in the cerebrospinal fluid of people with Alzheimer’s disease, consistently finding that levels of tau ...

Because of the prevalence of both TBI and Alzheimer's in humans ... through the autophagy-lysosome pathway, contributes to the accumulation of hyperphosphorylated tau in neurons and ...

Roche already has one Alzheimer’s candidate in its pipeline targeting tau, but has added a second via a deal with Belgian drugmaker UCB worth up to $2 billion. The Swiss pharma group is paying $ ...